[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Polish Mother Memorial Hospital Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,98,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100641078","the-impact-of-masseter-muscle-thickness-on-the-feeding-process-in-preterm-infants-in-ultrasound-assessment-100641078",false,"NCT07656467","The Impact of Masseter Muscle Thickness on the Feeding Process in Preterm Infants in Ultrasound Assessment","The Impact of Masseter Muscle Thickness on the Feeding Process in Preterm Infants in Ultrasound Assessment - an Observational Study","Inclusion Criteria:\n\n* 28+0\u002F7-32+0\u002F7 weeks of gestational age;\n* use of one specific type of teat;\n* passive oxygen therapy is permitted;\n* written informed consent obtained from parents.\n\nExclusion Criteria:\n\n* newborns with defects that may significantly affect the development of feeding function such as: cleft lip and\u002For palate, facial paralysis, and other craniofacial defects;\n* newborns with a shortened anterior lingual frenulum according to the E. Coryllos classification - meeting the criteria for frenotomy according to the Hazelbaker\u002FAmir scale;\n* detected genetic defects, metabolic diseases, or suspected cases of their presence;\n* newborns requiring intubation up to 10 days of life;\n* low Apgar score (less than 5 points at 5 and 10 minutes of life);\n* newborns with visible neurological disorders (e.g. with symptoms of hypertonia, impaired reflex reactions in the orofacial area) and\u002For significant abnormalities in central nervous system (CNS) imaging studies (e.g. III-IV degree intraventricular hemorrhages, CNS defects, hydrocephalus);\n* newborns of mothers with anhydramnios;\n* lack of consent to conduct at least two bottle-feeding sessions;\n* a child fed with a different type of teat than the one used in the study.","ALL","28 Weeks","32 Weeks",{"count":20,"type":21},30,"ESTIMATED","4 Months","OBSERVATIONAL","The aim of this study is to assess masseter muscle thickness using ultrasounds during oral feeding process in premature infants with gestational age from 28+0\u002F7 to 32+0\u002F7 weeks, taking into account the qualitative and quantitative aspects of oral feeding. The main question it aims to answer is: Does the thickness of the masseter muscle influence the course of development of the feeding function in premature newborns? The study will assess the influence of masseter muscle thickness on the oral feeding process in premature infants, which has significant cognitive value due to the dynamic development of feeding function in this group of newborns. Transitioning from enteral feeding via a nasogastric tube to full oral feeding is a crucial stage in the development of one of the most fundamental life functions - nutrition. Complete, effective, and safe oral feeding is also a factor in determining a newborn's discharge from the hospital. Research in the area of feeding is an important and ongoing goal for improving neonatal care in neonatal units. Furthermore, this study will provide preliminary data on masseter muscle thickness in premature infants, which may serve as a basis for further research.",[26],"Premature Infants",[28,29,30,31],"premature infant","masseter muscle","ultrasonography","oral feeding","NOT_YET_RECRUITING","2026-06-14",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":21},"2026-06",{"date":40,"type":21},"2029-12",{"name":42,"class":43},"Polish Mother Memorial Hospital Research Institute","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100584441","phase-1-use-of-intranasal-midazolam-to-reduce-stress-and-procedural-pain-in-premature-infants-during-routine-rop-examination-100584441","NCT06889376","Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.","The Use of Intranasal Sedation With Midazolam to Reduce Stress, Discomfort and Procedural Pain in Preterm Newborns and Infants During Routine ROP Screening","Inclusion Criteria:\n\n* Newborns qualified for ophthalmologic screening examination to detect retinopathy of prematurity (ROP):\n\n  a. Newborns\u002Finfants born before the 32 weeks of gestation and\u002For with a birth weight \\\u003C1500 g.\n* Obtaining informed consent from a parent\u002Flegal guardian.\n\nExclusion Criteria:\n\n* Newborns\u002Finfants not qualified for screening ophthalmologic examination (ROP).\n* Newborns\u002Finfants clinically unstable, with respiratory disorders\u002Fcardiovascular instability before the ophthalmologic examination.\n* Newborns\u002Finfants with congenital developmental defects.\n* Newborns\u002Finfants receiving analgesic\u002Fsedative medications for other reasons.","30 Weeks",{"count":53,"type":21},40,"INTERVENTIONAL",[56],"PHASE1","The goal of this study is to learn about the safety and effectiveness of intranasal midazolam in newborns and infants born prematurely, undergoing Retinopathy of Prematurity (ROP) screening.\n\nThe main question it aims to answer is:\n\n• Does use of intranasal midazolam is a safe, quick, non-invasive medication, that reduces the pain, stress, discomfort, and other complications in patients undergoing ROP screening?\n\nResearchers will compare the intervention group with a comparison group of the patients who will receive routine comfort care.",[59],"Drug Safety",[61,62,63],"intranasal midazolam","ROP screening","Premature infants","2025-03-16",{"date":66,"type":36},"2025-03-21",{"date":68,"type":21},"2025-03-24",{"date":70,"type":21},"2025-07-06",{"name":42,"class":43},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100582105","pmmhri-pitavastatin-registry-100582105","NCT06858982","PMMHRI-Pitavastatin Registry","The Polish Mother's Memorial Hospital Research Institute Pitavastatin Registry","Inclusion Criteria:\n\n* patient takling pitavastatin based on the 2021 Polish Lipid Guidelines\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":82,"type":21},500,"The PMMHRI-Pitavastatin Registry is a non-interventional, single-center registry conducted at the Polish Mother's Memorial Hospital Research Institute (PMMHRI). Established in January 2024, the registry enrolls all patients from the Department of Cardiology and Adult Congenital Heart Diseases, the Department of Endocrinology, as well as outpatient cardiology and endocrinology clinics who are prescribed pitavastatin.",[85],"Hypercholesterolemia",[87,88],"hypercholesterolemia","pitavastatin","RECRUITING","2025-02-27",{"date":92,"type":36},"2025-03-05",{"date":94,"type":36},"2024-06-01",{"date":96,"type":21},"2028-12",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":72},"100563015","the-prevalence-of-hyper-lpa-emia-in-the-pmmhri-lpa-registry-100563015","NCT06610669","The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry","The Prevalence, Patients' Characteristics, and Hyper-Lp(a)-Emia Risk Factors in the Polish Population. The Polish Mother's Memorial Hospital Research Institute Lipoprotein(a) Registry","Inclusion Criteria:\n\n* measured lipoprotein(a) concentration\n\nExclusion Criteria:\n\n\\-",{"count":106,"type":21},2000,"The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases, Department of Endocrinology, and outpatient cardiology and endocrinology clinics with the measured Lp(a) concentration have been included.",[109],"Lipoprotein(a), Hyper-Lp(a)-Emia",[111],"lipoprotein(a)","2024-09-23",{"date":114,"type":36},"2024-09-24",{"date":116,"type":36},"2022-01-01",{"date":118,"type":21},"2028-06",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":23,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":72},"100560014","pmmhri---familial-hypercholesterolemia-registry-100560014","NCT06571630","PMMHRI - Familial Hypercholesterolemia Registry","Polish Mother's Memorial Hospital Research Institute - Familial Hypercholesterolemia Registry","FH-Registry","Inclusion Criteria:\n\n* FH diagnosis\n\nExclusion Criteria:\n\n\\-","1 Day",{"count":130,"type":21},300,"1 Year","The registry is maintained at the Regional Centre for Rare Diseases, established in 2016, within Polish Mother's Memorial Hospital Research Institute. This facility diagnoses and treats over 80 distinct rare diseases in patients from across the country, including those with phenotypically or genetically confirmed familial hypercholesterolemia (FH).",[134],"Familial Hypercholesterolemia",[134],"2024-08-23",{"date":138,"type":36},"2024-08-26",{"date":140,"type":36},"2018-01-01",{"date":142,"type":21},"2025-12-31",{"name":42,"class":43},""]